A retrospective clinical audit was performed to assess if the British HIV Association 2011 guidelines on routine screening for tuberculosis in HIV are being implemented in a large UK urban clinic, and if a tuberculosis-screening prompt on the electronic patient record for new attendees was effective. Of 4658 patients attending during the inclusion period, 385 were newly diagnosed first-time attendees and routine tuberculosis screening was recommended in 165. Of these, only 6.1% of patients had a completed tuberculosis screening prompt, and 12.1% underwent routine tuberculosis screening. This audit represents the first published UK data on routine screening rates for tuberculosis in HIV and demonstrates low rates of tuberculosis screening despite an electronic screening prompt designed to simplify adherence to the national guideline. Reasons why tuberculosis screening rates were low, and the prompt ineffective, are unclear. A national audit is ongoing, and we await the results to see if our data reflect a lack of routine tuberculosis screening in HIV-infected patients at a national level.
Introduction
As part of the end tuberculosis (TB) strategy, the World Health Organization (WHO) recommends systematic testing for and treatment of latent TB infection in all people living with HIV. 1 Both the British HIV Association (BHIVA) and the National Institute of Health and Clinical Excellence (NICE) have issued UK national guidelines for latent TB screening in HIV patients. The BHIVA 2011 guidelines 2,3 recommend screening with an interferon-gamma release assay (IGRA) in patients from:
. Sub-Saharan Africa (SSA) on antiretroviral therapy (ART) for less than two years; . Medium-TB-incidence (MI) countries (Eastern Europe, Central Asia, North Africa, the Middle East, South Asia, East Asia, and the Caribbean) on ART for less than two years, with a CD4þ T-cell count <500 cells/mL;
. Low-TB-incidence (LI) countries (including the UK, Western Europe, Australia, USA, Canada, and New Zealand) on ART for less than six months, with a CD4þ T-cell count <350 cells/mL.
The NICE 2011 guidelines 4 recommend screening based on CD4þ T-cell count alone:
. <200 cells/mL, offer an IGRA and Mantoux test;
. 200-500 cells/mL, offer an IGRA AE Mantoux test.
The clinic population of the Mortimer Market Centre (MMC) in London represents a large urban cohort of HIV-infected patients. Routine TB screening as per the BHIVA guidelines was launched at this centre in October 2011, accompanied by an electronic TB screening prompt appearing when new HIV patients first attended the clinic. The user selected high, medium, or low TB incidence for the patient's country of birth, upon which the prompt detailed the BHIVA guideline criteria necessitating an IGRA being requested for that patient (i.e. if from SSA the user would select 'high incidence', and the prompt would state 'perform an IGRA if on ART for less than two years').
The aims of this audit are threefold: to assess the demographics of a large urban HIV clinical population, to determine the extent to which the BHIVA 2011 guidelines on routine TB screening are being implemented at this centre in newly diagnosed HIV patients, and to evaluate the effectiveness of an electronic TB screening prompt.
Methods
A retrospective audit of the electronic patient record (EPR) was used to identify all HIV-infected patients attending the clinic between 11 October 2011 and 31 December 2014 inclusive. For each patient, a computerised search was used to extract demographic data, CD4þ T-cell count at first attendance at MMC (baseline CD4þ T-cell count), IGRAs requested and their results, duration of follow-up, and electronic records of transfers of care to or from MMC.
The audit inclusion criteria were age >18 years, newly attending the clinic after the launch of TB screening on 11 October 2011 (patients were not screened retrospectively), have had the entirety of their HIV care at MMC (i.e. newly diagnosed at first attendance), have been followed-up for !180 days, have a recorded CD4þ T-cell count, and have a country of birth within a region for which the guidelines make explicit TB screening recommendations. Thus, only newly diagnosed patients who were only followed up at MMC and who fell into SSA, MI, or LI regions met the audit inclusion criteria.
Patients were stratified by their country of birth into SSA, MI, and LI screening groups. The specific countries composing world regions were taken from the UN regional classifications. 5 Given that only newly diagnosed patients were included, all patients were considered to be on ART for less than six months. Each patient's baseline CD4þ T-cell count and screening group were used to determine if TB screening would be recommended for that patient by the BHIVA guidelines, and if recommended whether an IGRA had been done. Only an IGRA that was not requested in the context of TB symptoms was considered to have been done for routine screening.
Demographic analysis was only undertaken for HIV patients meeting the audit inclusion criteria.
Results
During the inclusion period, 4658 HIV patients were followed up at the centre, of which 385 met the audit inclusion criteria. Salient demographic data are summarised in Table 1 .
TB screening was recommended in 165 (42.9%) of the 385 patients meeting the audit inclusion criteria. Of these, only 10 (6.1%) had a completed TB screening prompt, and only 20 (12.1%) underwent routine TB screening with an IGRA (Figure 1 ).
Discussion
This audit demonstrates low TB screening rates in HIV patients, despite an electronic prompt to facilitate screening. The prompt was under-utilised: it was completed in only 6.1% of patients on whom screening would have been recommended. The majority (54.8%) of patients were seen at first attendance by a consultant. Consultants only completed 30.4% of the completed prompts, but requested 65% of the screening IGRAs, indicating that the decision to perform an IGRA was generally made independent of the screening prompt.
The under-use of the prompt may be related to the complexity of the BHIVA 2011 guidelines, which risk stratify by three variables (country of birth, ART duration, and CD4þ T-cell count). The strategy advocated by NICE, using only CD4þ T-cell count, may be easier to implement and increase screening rates. A recent economic analysis of TB screening in HIV found that both the NICE and BHIVA strategies were costeffective when compared with no screening. 6 During the more recent study period (2005) (2006) (2007) (2008) (2009) (2010) , this analysis found the NICE guidelines to be less cost effective than the BHIVA guidelines, but noted that the NICE strategy is simpler and less likely to miss cases. Given the difficulty in implementing the BHIVA guidelines at this centre, which may be partially attributable to their added complexity and significant omissions in screening recommendations for many regions, it may well be that the NICE guidelines would be an overall more effective Figure 1 . Flowchart detailing use of the screening prompt and IGRAs performed for patients at MMC meeting the audit inclusion criteria and in whom TB screening was recommended.
